ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics, today announced Company management will participate at two upcoming investor conferences. Stifel 2024 Healthcare ConferenceFireside Chat on Monday, November 18th at 10:55 AM ET Stephens Annual Investment ConferenceFireside Chat on ...

MaxCyte, Inc. (MXCT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. I ...

文章核心观点 - 公司宣布任命Cynthia Collins为非执行董事,加入公司董事会 [1][2][3] - Collins拥有40多年生物技术和细胞基因医学领域的丰富经验,曾担任多家公司的CEO [2][3] - Collins加入后,公司董事会成员增加至10人 [1] 公司概况 - 公司是一家专注于细胞工程的领先公司,提供先进的平台技术,推动下一代细胞疗法和创新生物加工应用的发现、开发和商业化 [6] - 公司的ExPERT平台基于Flow Electroporation技术,可广泛应用于细胞疗法领域,从发现和开发到商业化 [6] - 公司拥有广泛的知识产权组合,为合作伙伴提供技术平台、科学、技术和监管支持,帮助他们转化人类健康 [6] 新任董事背景 - Cynthia Collins拥有丰富的生物技术行业和细胞基因医学经验 [2][3] - 曾担任多家公司的CEO,包括Editas Medicine、Human Longevity、GE Healthcare的细胞疗法和实验室业务、GenVec [2][3] - 目前在多家医疗保健公司担任董事,如Alanis Therapeutics、Nutcracker Therapeutics、Poseida Therapeutics等 [3] - 持有伊利诺伊大学香槟分校微生物学学士学位和芝加哥大学布斯商学院MBA学位 [3]

ROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the third quarter 2024 after the U.S. market close on Wednesday, November 6th, 2024. Company management will host a conference call to d ...

ROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024. In his new role, Mr. Soleymannezhad will lead MaxCyte's commercial ope ...

I've been following MaxCyte, Inc. ( MXCT ) for years now, since they IPO'ed on the London exchange (LSE: MXCT ). About a year ago, I wrote about MaxCyte's unique business model Jonquil Capital is a private investor, investment analyst, and writer from Smyrna, Georgia - the Jonquil city.Hopefully, by putting some words down in a page I can clarify my own thoughts on investment ideas and inspire worthwhile discussion and debate about the merits of these investments. I've been fully indoctrinated into the valu ...

ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of nextgeneration cell-based therapeutics and innovative bioprocessing applications, and Kamau Therapeutics, a clinical-stage stem cell therapy gene correction company, today announced they are entering into a strategic platform license (SPL) ...

ROCKVILLE, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced Company management will participate at the Virtual Craig-Hallum Capital Group Bioprocessing Conference on Thursday, September 19th at 9:30 am ET. A replay link of the event ...

财务数据和关键指标变化 - 总收入为10.4亿美元,同比增长15% [21] - 核心业务收入为7.6亿美元,同比下降9% [21] - 其中细胞治疗业务收入为6.2亿美元,同比下降6% [21] - 仪器收入为1.8亿美元,同比下降14% [21] - 租赁收入为2.6亿美元,基本持平 [21][22] - 加工装配(PA)收入为3亿美元,基本持平 [21][22] - SPL项目相关收入为2.9亿美元,同比增长263% [21][22] - 毛利率为86%,略高于上年同期的85% [23] - 总运营费用为20.9亿美元,略高于上年同期的20.7亿美元 [23] - 预计全年现金和投资余额将达到18亿美元,高于之前预期的17.5亿美元 [23] 各条业务线数据和关键指标变化 - 细胞治疗业务收入同比下降6%,但与上一季度基本持平 [32] - 药物发现业务收入同比下降18%,但与上一季度基本持平 [32][33] - 公司认为细胞治疗和药物发现业务的收入波动属正常情况,没有季节性 [33] 各个市场数据和关键指标变化 - 公司没有披露各个市场的具体数据和指标变化 [无] 公司战略和发展方向及行业竞争 - 公司将重点投资于高增长领域,特别是细胞治疗创新 [19][40][58] - 公司将缩减对VLX产品的投入和预期,将资源集中于细胞治疗这一大且可持续的增长机会 [19][42][43] - 公司认为细胞治疗将改变医疗格局,是公司长期发展的重点 [9][58] - 公司在细胞治疗领域拥有差异化的技术和服务优势,是行业首选平台 [14][40] 管理层对经营环境和未来前景的评论 - 尽管资金环境仍然谨慎,但公司对细胞治疗行业的长期发展前景保持乐观 [7][8][9] - 公司认为当前市场环境相对稳定,与上一季度基本持平,没有明显改善或恶化 [64][65] - 公司将保持谨慎乐观,不会过度依赖市场环境改善,而是专注于执行既定计划 [64] 其他重要信息 - 公司已有28个SPL客户,今年新签5个,包括全球领先的细胞治疗公司Legend Biotech [6][12][13] - 公司支持的CASGEVY获批成为首个获批的非病毒性细胞治疗,商业化前景广阔 [14][15][16] - 公司未来3-5年有5个SPL客户的产品有望获批,2028-2030年还有10个产品有望获批 [17][18][76][77] 问答环节重要的提问和回答 问题1 **Hannah Hefley 提问** 是否看到CASGEVY商业化对PA收入或租赁收入的影响 [29][30] **Doug Swirsky 回答** 公司不会单独披露CASGEVY对各项收入的具体影响,因为需要保密 [30] 问题2 **Julie Simmonds 提问** 公司今年已签5个SPL,未来是否还会有新签约 [35][36] **Doug Swirsky 回答** 公司过去一直保持3-5个新签SPL的节奏,未来也会继续保持这一节奏,但具体时间难以预测 [36] 问题3 **Joyce Ju 提问** 公司对未来2-3年内获批的5个产品和2028-2030年获批的10个产品的假设是什么 [76][77] **Maher Masoud 回答** 对于2027年的5个获批产品,公司预计其中3-4个将在2025年进入关键性试验阶段,另外1个已经在III期试验中。对于2028-2030年的10个获批产品,公司预计它们将在2026-2027年进入关键性试验。但具体成功概率公司难以预测。[77]

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 35.71%. A quarter ago, it was expected that this company would post a loss of $0.14 per share when it actually produced a loss of $0.09, delivering a surprise of 35.71%. Over the last four quarters, the company has surpassed ...